Oxidized high-density lipoprotein enhances inflammatory activity in rat mesangial cells

Diabetes/Metabolism Research and Reviews

Volumn 26, Issue 6, 2010, Pages 455-463

  Zhang, Miao ^a   Gao, Xiang ^b   Wu, Jianxiang ^b   Liu, Dongmei ^b   Cai, Houan ^b   Fu, Lili ^b   Mei, Changlin ^b  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Inflammation; Oxidized HDL; Rat mesangial cells; Scavenger receptor

Indexed keywords

CD36 ANTIGEN; CHEMOATTRACTANT; CXCL11 CHEMOKINE; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; RANTES; REACTIVE OXYGEN METABOLITE; SCAVENGER RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; INCUBATION TIME; LIPID OXIDATION; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; UPREGULATION;

ANIMALS; ANTIGENS, CD36; APOPTOSIS; CHEMOKINE CCL2; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIPOPROTEINS, HDL; MESANGIAL CELLS; NF-KAPPA B; OXIDATION-REDUCTION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; REACTIVE OXYGEN SPECIES; SCAVENGER RECEPTORS, CLASS B; SCAVENGER RECEPTORS, CLASS E; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956646581     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1102     Document Type: Article

References (29)

1. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms and potential consequences. Am J Physiol Renal Physiol 2006; 290: 262-272.
2. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
3. Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005; 16: 529-538.
4. Santini E, Lupi R, Baldi S, et al. Effects of different LDL particles on inflammatory molecules in human mesangial cells. Diabetologia 2008; 51: 2117-2125.
5. Davidson MH, Toth PP. High-density lipoprotein metabolism: potential therapeutic targets. Am J Cardio 2007; 100: n32-n40.
6. Ansell BJ, Navab M, Hama S, et al. Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003; 108: 2751-2756.
7. Ferretti G, Bacchetti T, Negre-Salvayre A, Salvayre R, Dousset N, Curatola G. Structural modifications of HDL and functional consequences. Atherosclerosis 2006; 184: 1-7.
8. Francis GA. High density lipoprotein oxidation: in vitro susceptibility and potential in vivo consequences. Biochim Biophys Acta 2000; 1483: 217-235.
9. Yu R, Yekta B, Vakili L, et al. Proatherogenic high-density lipoprotein, vascular inflammation, and mimetic peptides. Curr Atheroscler Rep 2008; 10: 171-176.
10. Tsumura M, Kinouchi T, Ono S, Nakajima T, Komoda T. Serum lipid metabolism abnormalities and change in lipoprotein contents in patients with advanced-stage renal disease. Clinica Chimica Acta 2001; 314: 27-37.
11. Vaziri ND, Moradi H, Pahl MV, Fogelman AM, Navab M. In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney Int 2009; 76: 437-444.
12. Matsunaga T, Hokari S, Koyama I, Harada T, Komoda T. NFkappa B activation in endothelial cells treated with oxidized high-density lipoprotein. Biochem Biophys Res Commun 2003; 303: 313-319.
13. Assinger A, Schmid W, Eder S, Schmid D, Koller E, Volf I. Oxidation by hypochlorite converts protective HDL into a potent platelet agonist. FEBS Lett 2008; 582: 778-784.
14. Nuszkowski A, Grabner R, Marsche G, Unbehaun A, Malle E, Heller R. Hypochlorite-modified low density lipoprotein inhibits nitric oxide synthesis in endothelial cells via an intracellular dislocalization of endothelial nitric-oxide synthase. J Biol Chem 2001; 276: 14212-14221.
15. Valiyaveettil M, Kar N, Ashraf MZ, Byzova TV, Febbraio M, Podrez EA. Oxidized high-density lipoprotein inhibits platelet activation and aggregation via scavenger receptor BI. Blood 2008; 111: 1962-1971.
16. Liu HT, Li WM, Xu G, et al. Chitosan oligosaccharides attenuate hydrogen peroxide-induced stress injury in human umbilical vein endothelial cells. Pharmacol Res 2009; 59: 167-175.
17. Makino H, Sugiyama H, Kashihara N. Apoptosis and extracellular matrix cell interactions in kidney disease. Kidney Int 2000; 58: S67-S75.
18. Varghese Z, Fernando R, Moorhead JF, Powis SH, Ruan XZ. Effects of sirolimus on mesangial cell cholesterol homeostasis: a novel mechanism for its action against lipid-mediated injury in renal allografts. Am J Physiol Renal Physiol 2005; 289: F43-F48.
19. Sawamura T, Kume N, Aoyama T, et al. An endothelial receptor for oxidized low-density lipoprotein. Nature 1997; 386: 73-77.
20. Dentelli P, Rosso A, Zeoli A, et al. Oxidative stress-mediated mesangial cell proliferation requires RAC-1/reactive oxygen species production and beta 4 integrin expression. J Biol Chem 2007; 282: 26101-26110.
21. Wolf G, Wenzel U, Jablonski K, Brundert M, Rinninger F. Angiotensin II down-regulates the SR-BI HDL receptor in proximal tubular cells. Nephrol Dial Transplant 2005; 20: 1222-1227.
22. Leung JC, Tang SC, Chan LY, Chan WL, Lai KN. Synthesis of TNF-alpha by mesangial cells cultured with polymeric anionic IgA - role of MAPK and NF-kappaB. Nephrol Dial Transplant 2008; 23: 72-81.
23. Bouma HR, Ploeg RJ, Schuurs TA. Signal transduction pathways involved in brain death-induced renal injury. Am J Transplant 2009; 9: 989-997.
24. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357: 1301-1310.
25. Ansell BJ, Fonarow GC, Fogelman AM. The paradox of dysfunctional high density lipoprotein. Curr Opin Lipidol 2007; 18: 427-434.
26. Okamura DM, López-Guisa JM, Koelsch K, Collins S, Eddy AA. Atherogenic scavenger receptor modulation in the tubulointerstitium in response to chronic renal injury. Am J Physiol Renal Physiol 2007; 293: F575-F585.
27. Iwao Y, Nakajou K, Nagai R, et al. CD36 is one of important receptors promoting renal tubular injury by advanced oxidation protein products. Am J Physiol Renal Physiol 2008; 295: F1871-F1880.
28. Febbraio M, Podrez EA, Smith JD, et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 2000; 105: 1049-1056.
29. Primo L, Ferrandi C, Roca C, et al. Identification of CD36 molecular features required for its in vitro angiostatic activity. Faseb J 2005; 19: 1713-1715.